Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 3% – Here’s Why

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was up 3% on Monday . The stock traded as high as $11.90 and last traded at $11.93. Approximately 195,038 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 750,368 shares. The stock had previously closed at $11.58.

Wall Street Analysts Forecast Growth

FULC has been the topic of a number of recent analyst reports. Bank of America raised their price target on Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research report on Tuesday, December 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Leerink Partners set a $20.00 price target on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Finally, Royal Bank Of Canada lifted their price objective on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Fulcrum Therapeutics currently has an average rating of “Hold” and an average target price of $19.00.

Fulcrum Therapeutics Trading Up 2.6%

The stock has a 50 day moving average price of $10.39 and a 200 day moving average price of $8.49. The company has a market capitalization of $642.95 million, a P/E ratio of -10.07 and a beta of 3.17.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, research analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Insiders Place Their Bets

In related news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total value of $165,450.00. Following the sale, the director owned 484,864 shares of the company’s stock, valued at $5,348,049.92. The trade was a 3.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. The trade was a 40.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is currently owned by insiders.

Institutional Trading of Fulcrum Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC boosted its stake in shares of Fulcrum Therapeutics by 5.9% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock valued at $49,505,000 after purchasing an additional 298,100 shares during the last quarter. Nantahala Capital Management LLC raised its stake in Fulcrum Therapeutics by 0.9% during the first quarter. Nantahala Capital Management LLC now owns 4,822,693 shares of the company’s stock worth $13,889,000 after buying an additional 42,985 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Fulcrum Therapeutics by 53.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock valued at $31,572,000 after buying an additional 1,589,000 shares during the period. Balyasny Asset Management L.P. boosted its position in Fulcrum Therapeutics by 8.4% during the third quarter. Balyasny Asset Management L.P. now owns 1,450,480 shares of the company’s stock valued at $13,344,000 after acquiring an additional 112,266 shares during the last quarter. Finally, Exome Asset Management LLC grew its holdings in Fulcrum Therapeutics by 143.0% during the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock worth $1,985,000 after acquiring an additional 405,538 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.